Once you have started taking Esbriet® (pirfenidone), it's important to continue having a good relationship with your doctor and healthcare team. Having clear communication helps you better understand idiopathic pulmonary fibrosis (IPF) and helps your healthcare team better support you.
Talk to your doctor about:
Keeping daily records of your health can help your doctor see how you’re doing on your IPF treatment goals.
When I have questions about side effects, I call my doctor’s office. From the beginning, I got on a first-name basis with the nurse practitioner, and she helped me an awful lot. Communication with your healthcare team is very important, so never hesitate to contact them. I always let them know when I need help dealing with a problem.”
Jim
Esbriet Ambassador
Centers for Medicare & Medicaid Services. Advance notice of methodological changes for calendar year (CY) 2018 for Medicare Advantage (MA) capitation rates, Part C and Part D payment policies and 2018 call letter. https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Downloads/Advance2018.pdf. Posted February 1, 2017. Accessed October 17, 2017.
Centers for Medicare & Medicaid Services. Advance notice of methodological changes for calendar year (CY) 2018 for Medicare Advantage (MA) capitation rates, Part C and Part D payment policies and 2018 call letter. https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Downloads/Advance2018.pdf. Posted February 1, 2017. Accessed October 17, 2017.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.